Evidence map›Paper›PMID 36896420›Full record

ArticleFrontiers in aging neuroscience2023

A progression analysis of motor features in Parkinson's disease based on the mapper algorithm.

Ling-Yan Ma, Tao Feng, Chengzhang He, Mujing Li, Kang Ren, Junwu Tu

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Ling-Yan MaDepartment of Neurology, Center for Movement Disorders, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Tao FengDepartment of Neurology, Center for Movement Disorders, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Chengzhang HeInstitute of Mathematical Sciences, ShanghaiTech University, Shanghai, China.
Mujing LiInstitute of Mathematical Sciences, ShanghaiTech University, Shanghai, China.
Kang RenGYENNO Science Co., LTD., Shenzhen, China.
Junwu TuInstitute of Mathematical Sciences, ShanghaiTech University, Shanghai, China.

Funding

Developing, evaluating, and disseminating new methods and technologies to advance Parkinson disease researchP20NS092529 · NINDS · UNIVERSITY OF ROCHESTER · PI DORSEY, EARL RAY · 2015 to 2016
$767k
NINDS NIH HHS P20 NS092529
6 · The paper itself

Abstract

Background: Parkinson's disease (PD) is a neurodegenerative disease with a broad spectrum of motor and non-motor symptoms. The great heterogeneity of clinical symptoms, biomarkers, and neuroimaging and lack of reliable progression markers present a significant challenge in predicting disease progression and prognoses. Methods: We propose a new approach to disease progression analysis based on the mapper algorithm, a tool from topological data analysis. In this paper, we apply this method to the data from the Parkinson's Progression Markers Initiative (PPMI). We then construct a Markov chain on the mapper output graphs. Results: The resulting progression model yields a quantitative comparison of patients' disease progression under different usage of medications. We also obtain an algorithm to predict patients' UPDRS III scores. Conclusions: By using mapper algorithm and routinely gathered clinical assessments, we developed a new dynamic models to predict the following year's motor progression in the early stage of PD. The use of this model can predict motor evaluations at the individual level, assisting clinicians to adjust intervention strategy for each patient and identifying at-risk patients for future disease-modifying therapy clinical trials.

Indexed as

mapper algorithmMarkov chainParkinson's diseaseprediction modelprogression analysis

Identifiers

PMID36896420
PMCPMC9989279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.